Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

Report documents

1. Extract of dossier assessment

   Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

   published on

   01.08.2017

   Document type

   PDF document, 216 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 216 kB, EN, not accessible)
2. Dossier assessment

   Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

   published on

   01.08.2017

   Document type

   PDF document, 579 kB, DE, not accessible

   Download file : Dossier assessment (PDF document, 579 kB, DE, not accessible)

Dossier assessment

Project details

Project no.

A17-19

Commission

Commission awarded on 01.05.2017 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Cancer

Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

1. Addendum

   Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19

   Project no.

   A17-44

   Last updated

   19.10.2017

   Status: Commission completed

2. Dossier assessment

   Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A24-73

   Last updated

   16.01.2025

   Status: Commission completed